Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

被引：0

作者：

Kavgaci, Akif ^{[1
]}

Kula, Serdar ^{[1
]}

Incedere, Fatma ^{[1
]}

Terlemez, Semiha ^{[1
]}

Tunaoglu, Fatma Sedef ^{[1
]}

机构：

[1] Gazi Univ, Fac Med, Dept Pediat, Div Pediat Cardiol, Ankara, Turkiye

来源：

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 2023年 / 31卷 / 01期

关键词：

Pulmonary arterial hypertension; subcutaneous; treprostinil;

D O I：

10.5606/tgkdc.dergisi.2023.23748

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.

引用

页码：145 / 148

页数：4

共 50 条

[31] Outpatient Subcutaneous Treprostinil for Pediatric Single Ventricle Patients
Siehr, S. L.
Ogawa, M.
Romfh, A.
Rosenthal, D. N.
Feinstein, J. A.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S159 - S159
[32] Use of Cardiac Magnetic Resonance Imaging to Assess Response to Oral Treprostinil Therapy in Pediatric Pulmonary Hypertension Patients
Gaviria, Susana
Kollar, Sarah
Loke, Yue-Hin
Truong, Uyen
CIRCULATION, 2024, 150
[33] Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension
Keogh, Anne M.
Jabbour, Andrew
Weintraub, Robert
Brown, Karen
Hayward, Chris S.
Macdonald, Peter S.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (11): : 1079 - 1083
[34] The Effect of Subcutaneous Treprostinil on Pulmonary Hypertension Associated with Interstitial Lung Disease
Sadushi-Kolici, Roela
Shafran, Inbal
Prosch, Helmut
Skoro-Sajer, Nika
Gerges, Christin
Lang, Irene
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[35] Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
Vachiéry, JL
Hill, N
Zwicke, D
Barst, R
Blackburn, S
Naeije, R
CHEST, 2002, 121 (05) : 1561 - 1565
[36] The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
Jansa, Pavel
Kopec, Grzegorz
Torbicki, Adam
Sadushi-Kolici, Roela
Campean, Ioana-Alexandra
Halank, Michael
Simkova, Iveta
Steringer-Mascherbauer, Regina
Salobir, Barbara
Klepetko, Walter
Lindner, Jaroslav
Lang, Irene M.
PULMONARY CIRCULATION, 2023, 13 (03)
[37] Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension
Mouratoglou, Sophia Anastasia
Patsiala, Anthoula
Feloukidis, Christos
Karvounis, Haralambos
Giannakoulas, George
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 187 - 189
[38] Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension
Kochanski, Justin J.
Feinstein, Jeffrey A.
Ogawa, Michelle
Ritter, Victor
Hopper, Rachel K.
Adamson, Gregory T.
PULMONARY CIRCULATION, 2024, 14 (01)
[39] SWITCHING FROM SUBCUTANEOUS TREPROSTINIL TO INHALED TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION TREATMENT AND ECONOMIC IMPACT EVALUATION
Moya-Carmona, I
Pedrosa Ruiz, M.
Estaun-Martinez, C.
Ortiz, J.
Mora-Santiago, M. R.
VALUE IN HEALTH, 2018, 21 : S405 - S405
[40] Combination of Balloon Pulmonary Angioplasty and Subcutaneous Treprostinil for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Gerges, C.
Kopec, G.
Sadushi-Kolici, R.
Skoro-Sajer, N.
Gerges, M.
Matsubara, H.
Lang, I. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199

← 1 2 3 4 5 →